TRANSFORMING LIVES. ELEVATING CARE.

Teikoku Pharma develops life-changing therapies through advanced science and technical ingenuity.

LATEST NEWS

Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.

Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery

Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula

OUR STORY

Teikoku Pharma USA is a global specialty pharmaceutical company with a focus on developing first and best-in-class therapeutic products in the areas of pain management, CNS disorders, and Dermatology. Our Lidoderm product has helped millions of patients in 59 countries.

We explore a variety of opportunities to develop drugs that improve patient lives and take an opportunistic approach to our programs, both independently and collaboratively with like-minded partners.

TPU-006: 4-Day Dexmedetomidine Patch

TPU-006: 4-Day Dexmedetomidine Patch

TPU-006 is an investigational non-opioid analgesic designed to deliver dexmedetomidine for four days or longer post-surgery.

PRODUCT PORTFOLIO

Lidoderm®
Lidocaine 5% Patch (US)

Lidoderm was the first prescription hydrogel patch approved in the United States for post-herpetic neuralgia (PHN). This pioneering transdermal technology provides pain relief after a shingles infection for up to three days.

Versatis®
Lidocaine 5% Patch (Europe)

A topical 5% medicated lidocaine plaster prescribed for the management of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN)1, also known as after-shingles pain.

Docetaxel
Alcohol-free Injection

Docetaxel is a non-alcohol taxane injection indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

RESEARCH & DEVELOPMENT

Uncovering What’s Possible

With deep expertise in dosage form development plus comprehensive manufacturing capabilities, we create both the formulations and the delivery mechanisms that bring innovative ideas to life.

FEATURED NEWS

News

Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.

News

Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

News

Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China

News

Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China

News

Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery

News

Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula